Chronic Myeloid Leukemia News and Research

RSS
Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.
MIT researchers use disarmed version of anthrax toxin to deliver cancer drugs

MIT researchers use disarmed version of anthrax toxin to deliver cancer drugs

Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Paradigm shift in new, highly targeted leukaemia therapy

Paradigm shift in new, highly targeted leukaemia therapy

NCCN ORP awards six grants to improve care for patients with renal or hematologic malignancies

NCCN ORP awards six grants to improve care for patients with renal or hematologic malignancies

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

New database allows researchers to match old drugs for new diseases

New database allows researchers to match old drugs for new diseases

BioLineRx announces financial results for Q1 2014, provides operational update

BioLineRx announces financial results for Q1 2014, provides operational update

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD provides update on corporate developments, reports Q1 2014 financial results

Teva's SYNRIBO for injection receives FDA approval for home administration

Teva's SYNRIBO for injection receives FDA approval for home administration

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

FDA grants full approval of SYNRIBO for injection

FDA grants full approval of SYNRIBO for injection

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

Study examine effect of high out-of-pocket drug costs for targeted cancer therapies on patients

Study examine effect of high out-of-pocket drug costs for targeted cancer therapies on patients

Experimental drug inhibits BTK molecule in patients with chronic lymphocytic leukemia

Experimental drug inhibits BTK molecule in patients with chronic lymphocytic leukemia

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients